Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by Leerink Partners

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Partners in a research note issued to investors on Monday, Marketbeat reports. They presently have a $60.00 target price on the stock. Leerink Partners’ price objective indicates a potential upside of 27.99% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 17th. Oppenheimer reaffirmed an “outperform” rating and set a $52.00 target price on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Finally, B. Riley lifted their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.67.

Kymera Therapeutics Stock Up 1.4 %

KYMR stock opened at $46.88 on Monday. The business’s fifty day moving average is $43.34 and its 200-day moving average is $38.81. The company has a market cap of $2.88 billion, a P/E ratio of -18.68 and a beta of 2.22. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $50.19.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The company’s revenue was up 55.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.67) EPS. Research analysts anticipate that Kymera Therapeutics will post -2.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The disclosure for this sale can be found here. Insiders have sold 482,105 shares of company stock valued at $18,651,584 in the last 90 days. Company insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. lifted its position in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the last quarter. Comerica Bank lifted its position in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the last quarter. Keudell Morrison Wealth Management lifted its position in Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after buying an additional 480 shares during the last quarter. Congress Asset Management Co. MA lifted its position in Kymera Therapeutics by 1.2% in the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after buying an additional 533 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in Kymera Therapeutics by 4.7% in the first quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock valued at $486,000 after buying an additional 547 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.